Flotate receptor-targeted liposomes with encapsulated anti-sarcosine antibodies for attenuation of prostate tumors

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216305%3A26620%2F16%3APU122191" target="_blank" >RIV/00216305:26620/16:PU122191 - isvavai.cz</a>

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Flotate receptor-targeted liposomes with encapsulated anti-sarcosine antibodies for attenuation of prostate tumors

Popis výsledku v původním jazyce

Prostate cancer is the most occurring malignancy in men from USA or Western Europe with 29% of men of 30 to 40 years of age and 64% of men of 60 to 70 years of age suffering from prostate cancer [1]. One of the delineated oncometabolites in prostate cancer is the amino acid sarcosine (N-methylglycine) that plays a substantial role in progression of prostate cancer[2]. In this work, anti-sarcosine antibodies were employed for attenuation of prostate tumours in xenograft mice. The antibodies were modified with CdTe quantum dots for the detection of their intracellular delivery. Free antibodies are unable to enter intracellular space, so to enable internalization of these antibodies in the tumour intracellular space needed for subsequent neutralization of sarcosine, the antibodies were encapsulated in liposomes with loading efficiency of 69.2%. To increase the shuttling efficiency of antibodies-loaded liposomes, their surface was modified with folate, enabling entering of tumour cells via clathrin-mediat

Název v anglickém jazyce

Flotate receptor-targeted liposomes with encapsulated anti-sarcosine antibodies for attenuation of prostate tumors

Popis výsledku anglicky

Prostate cancer is the most occurring malignancy in men from USA or Western Europe with 29% of men of 30 to 40 years of age and 64% of men of 60 to 70 years of age suffering from prostate cancer [1]. One of the delineated oncometabolites in prostate cancer is the amino acid sarcosine (N-methylglycine) that plays a substantial role in progression of prostate cancer[2]. In this work, anti-sarcosine antibodies were employed for attenuation of prostate tumours in xenograft mice. The antibodies were modified with CdTe quantum dots for the detection of their intracellular delivery. Free antibodies are unable to enter intracellular space, so to enable internalization of these antibodies in the tumour intracellular space needed for subsequent neutralization of sarcosine, the antibodies were encapsulated in liposomes with loading efficiency of 69.2%. To increase the shuttling efficiency of antibodies-loaded liposomes, their surface was modified with folate, enabling entering of tumour cells via clathrin-mediat

Druh

O - Ostatní výsledky

CEP obor

—

OECD FORD obor

10603 - Genetics and heredity (medical genetics to be 3)

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2016

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů